Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-04-22-Speech-2-394"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20080422.52.2-394"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"I thank the honourable Member for the question. I would say that the Commission is well aware of the unprecedented situation caused by the spread of bluetongue in several Member States in recent years and is making strenuous efforts to combat this disease.
Last January, at the Conference on bluetongue vaccination arranged by the Commission, it clearly emerged that vaccination is the main, most effective veterinary measure to combat bluetongue. In order to achieve a harmonised EU approach, the Commission swiftly issued guidelines and criteria for vaccination plans, while leaving the Member States the necessary flexibility to adapt the vaccination strategy to their particular situation.
The Commission then assessed the plans submitted by the Member States, approved them and ensured a first financial contribution of up to EUR 64 million out of a total of EUR 130 million for the whole exercise. All these actions reflect the importance that the Commission attaches to the vaccination.
The Community is also supporting several bluetongue research programmes. Under the fifth and sixth framework programmes, two specific projects were devoted to the development of a safe, efficacious bluetongue virus vaccination strategy. The EU contribution was EUR 1.7 million and EUR 804 000 respectively. These actions will have continuity in the seventh framework programme. However, at present scientists do not consider that the development of anti-viral treatments would effectively reduce the losses caused by this disease."@en1
|
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples